Research Laboratory, IBIMA, Regional University Hospital of Malaga, UMA, M alaga, Spain. RATIONALE: Nasal allergen challenge (NAC) is the gold standard for the diagnosis of allergic rhinitis (AR) phenotypes. However, studies on its diagnostic reliability and safety in rhinitis patients with-and withoutasthma are scarce. Our aim was to analyse the accuracy and safety of NAC in asthmatic and non-asthmatic rhinitis patients. METHODS: We retrospectively evaluated NAC performed in AR, local allergic rhinitis (LAR), non-allergic rhinitis (NAR) patients, and controls monitored by total nasal-ocular symptoms label-score (TNOSS) and percentage of change in volume 2-6cm in acoustic rhinometry (Dvol2-6cm). The accuracy of NAC, and optimum cut-off points of TNOSS and Dvol2-6cm were calculated by receiver operating characteristic (ROC) curves. Safety was explored by the registration of adverse events (AE) in asthmatic and non-asthmatic patients. Two methods of allergen application (nasal spray vs micropipette) and protocols of NAC with a single or multiple allergens (NAC-S vs NAC-M) were compared. RESULTS: We evaluated 11499 NAC performed in 6348 subjects (96% patients and 4% controls). The optimum cut-off points were Dvol2-6cm> _25% (AR and LAR: sensitivity 99%, specificity 100%, PPV 100%, NPV 98%), and TNOSS> _4 for AR (sensitivity 69%, specificity 90%, PPV 90%, NPV 96%) and LAR (sensitivity 55%, specificity 90%, PPV 90%, NPV 55%). No bronchial or systemic AE occurred. Four patients (1 asthmatic and 3 non-asthmatics) had a mild-moderate local oropharynx AE, with normal auscultation and spirometry. CONCLUSIONS: Nasal allergen challenge is a high accuracy and safety diagnostic test in asthmatic-and non-asthmatic rhinitis patients that can be used in clinical practise. 
RESULTS:
In NLF samples obtained from positive NAPTs (LAR patients), certain MP levels were significantly elevated at 15 minutes after NAPTs compared with baseline: activated mast cell MPs (2.1-fold increase, p50.02), activated basophil MPs (2.6-fold increase, p50.02) and epithelial MPs (2.1-fold increase, p50.01). However, there was no change in these three MP levels at 15 minutes after negative NAPTs (non-AR patients) compared with baseline (activated mast cell MPs: p50.13, activated basophil MPs: p50.6, epithelial MPs: p50.16). Interestingly, we did not find a change in levels of activated eosinophil MPs after either positive (p50.38) or negative (p50.31) NAPTs. CONCLUSIONS: Based on MP levels analysis, epithelial injury is induced and mast cells and basophils get activated after positive NAPTs in LAR patients, without evidence of eosinophils activation in this cohort. Measuring MPs in the NLF may be useful in both diagnosing LAR and better elucidating its pathophysiology.
